Chronic PPARγ Stimulation Shifts Amyloidosis to Higher Fibrillarity but Improves Cognition
Tanja Blume, Maximilian Deußing, Gloria Biechele, Finn Peters, Benedikt Zott, Claudio Schmidt, Nicolai Franzmeier, Karin Wind-Mark, Florian Eckenweber, Christian Sacher, Yuan Shi, Katharina Ochs, Gernot Kleinberger, Xianyuan Xiang, Carola Focke, , Matthias Brendel
This study shows that chronic PPARγ agonist treatment increases amyloid-beta fibrillarity but improves cognition and synaptic density in mouse models.
Frontiers in Aging Neuroscience · Mar 30, 2022Peer-reviewedNeuroscience